VivoSeq
Infectious Disease

Oral Candidiasis

6

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

Oral Candidiasis is an early-stage landscape with 6 programs across 4 companies. The most active players are Pacgen Biopharmaceuticals Corporation, Bayer, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

0/100

Mech. Concentration

67/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pacgen Biopharmaceuticals Corporation

1 program

Phase 2Bayer logo

Bayer

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Completed3 · 100%

Clinical Trials

Trial Activity

Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT00002057
Novel Rinse to Treat in Oral Candidiasis in Cancer Patients
Completed·BBiomedical Development Corporation·N/A·NCT00612963·23 enrolled
Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis
Completed·PPacgen Biopharmaceuticals Corporation·Phase 2·NCT00659971·223 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)